OptiBiotix Health PLC Joint Product Agreement with multinational (6270R)
December 13 2016 - 1:00AM
UK Regulatory
TIDMOPTI
RNS Number : 6270R
OptiBiotix Health PLC
13 December 2016
OptiBiotix Health plc
("OptiBiotix" or "the Company")
Joint Product Agreement with multinational
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing products to tackle obesity, high cholesterol and
diabetes, announces that it has entered into a joint development
agreement (the "Agreement") with a multinational. The Agreement
allows for the development of food and Over The Counter ("OTC")
products containing OptiBiotix's SlimBiome(R) technology for the
Asian market.
The multinational is a major supplier of nutritional solutions
to the food, beverage, nutraceutical and pharmaceutical industries
within Asia, and increasingly across global markets.
The aim of the Agreement is to develop weight management
products containing SlimBiome(R) technology in a range of foods and
OTC products which, if successful, will be launched into the Asian
market in the second half of 2017.
The Company requires its identity and commercial details to
remain confidential and no further details can be disclosed at this
time.
Discussions are ongoing and it is hoped a further announcement
can be made in due course.
Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to
announce the signing of this Agreement with a multinational which
creates the opportunity to launch products containing OptiBiotix's
SlimBiome(R) into the Asian market next year. The multinational is
a leading supplier of food ingredients with many well-known and
respected brands and a multibillion dollar turnover. With India
(30m) and China (46m) ranked second and third in having the highest
number of overweight people in the world we hope that OptiBiotix's
strong science base together with our partner's local knowledge,
reputation, and sales and distribution capability will bring the
benefits of SlimBiome(R) technology to a wider audience."
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP Tel: 020 7213
0880
Liam Murray
finnCap Broker Tel: 020 7220
0500
Adrian Hargrave / Scott Mathieson
/ Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741
001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCEAXAAFAKKFFF
(END) Dow Jones Newswires
December 13, 2016 02:00 ET (07:00 GMT)